Table 1.
The cell survival values and in vitro cytotoxicity of 2a–2e in three different cancer cell lines [35].
| Compound | CS Values [%] (Mean ± SD) a | IC50 [μM] (Mean ± SD) b | ||||
|---|---|---|---|---|---|---|
| HepG2 c | LU-1 d | RD e | HepG2 c | LU-1 d | RD e | |
| 2a | 0 | 18.51 ± 1.20 | 67.13 ± 2.17 | 3.24 ± 0.22 | 2.55 ± 0.12 | >100 ± 1.45 |
| 2b | 97.01 ± 0.90 | 76.47 ± 2.00 | 95.57 ± 1.90 | >100 ± 1.32 | >100 ± 0.97 | >100 ± 0.58 |
| 2c | 5.98 ± 0.39 | 0 | 0 | 2.73 ± 0.12 | 1.76 ± 0.11 | 2.63 ± 0.10 |
| 2d | 43.98 ± 1.46 | 25.21 ± 1.34 | 72.82 ± 1.26 | 7.21 ± 0.57 | 4.56 ± 0.24 | >100 ± 1.28 |
| 2e | 60.88 ± 1.80 | 67.52 ± 2.33 | 65.52 ± 1.54 | >100 ± 2.10 | >100 ± 1.43 | >100 ± 1.45 |
| ellipticine f | 1.25 ± 0.30 | 1.87 ± 0.20 | 0 | 1.22 ± 0.09 | 1.30 ± 0.10 | 1.18 ± 0.08 |
a The concentration of the sample c = 5 µg · mL−1. CS (cell survival) value [%] is the ability of cells to survive at a certain concentration of the reagent [in %] compared with the control (n = 3); b Data are presented as means of the concentration of the sample required for 50% inhibition of cell growth ± SD from triplicated; c HepG2 (human hepatocellular carcinoma); d LU-1 (human lung adenocarcinoma); e RD (human rhabdomyosarcoma); f ellipticine (5,11-dimethyl-6H-pyrido[4,3-b]carbazole) was used as a positive control.